{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:26:37Z","timestamp":1776270397114,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T00:00:00Z","timestamp":1533772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s12031-018-1133-z","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T02:09:57Z","timestamp":1533780597000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Effects of Iloperidone on Cerebral Serotonin and Adrenoceptor Subtypes"],"prefix":"10.1007","volume":"66","author":[{"given":"Yong Kee","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-9378","authenticated-orcid":false,"given":"Frank I.","family":"Tarazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,9]]},"reference":[{"issue":"4","key":"1133_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1046\/j.1471-4159.2003.02044.x","volume":"87","author":"M Amarg\u00f3s-Bosch","year":"2003","unstructured":"Amarg\u00f3s-Bosch M, Adell A, Bortolozzi A, Artigas F (2003) Stimulation of alpha1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs. J Neurochem 87(4):831\u2013842","journal-title":"J Neurochem"},{"issue":"4","key":"1133_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2146\/ajhp100079","volume":"68","author":"SA Arif","year":"2011","unstructured":"Arif SA, Mitchell MM (2011) Iloperidone: a new drug for the treatment of schizophrenia. Am J Health Syst Pharm 68(4):301\u2013308","journal-title":"Am J Health Syst Pharm"},{"key":"1133_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00213-003-1724-3","volume":"174","author":"AF Arnsten","year":"2004","unstructured":"Arnsten AF (2004) Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology 174:25\u201331","journal-title":"Psychopharmacology"},{"key":"1133_CR4","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1056\/NEJM199103143241107","volume":"324","author":"RJ Baldessarini","year":"1991","unstructured":"Baldessarini RJ, Frankenburg FR (1991) Clozapine\u2013a novel antipsychotic agent. N Engl J Med 324:746\u2013754","journal-title":"N Engl J Med"},{"key":"1133_CR5","first-page":"461","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"RJ Baldessarini","year":"2005","unstructured":"Baldessarini RJ, Tarazi FI (2005) Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker K (eds) Goodman and Gilman\u2019s the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 461\u2013500"},{"key":"1133_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.neuropharm.2006.04.004","volume":"51","author":"AM Barr","year":"2006","unstructured":"Barr AM, Powell SB, Markou A, Geyer MA (2006) Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 51:457\u2013465","journal-title":"Neuropharmacology"},{"key":"1133_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0893-133X(95)00068-O","volume":"13","author":"N Brunello","year":"1995","unstructured":"Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995) New insights into the biology of schizophrenia through the action mechanism of clozapine. Neuropsychopharmacology 13:177\u2013213","journal-title":"Neuropsychopharmacology"},{"key":"1133_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00213-003-1639-z","volume":"172","author":"M Cahir","year":"2004","unstructured":"Cahir M, Mawhinney T, King DJ (2004) Differential region-specific regulation of central alpha 1-adrenoceptor binding following chronic haloperidol and clozapine administration in the rat. Psychopharmacology 172:196\u2013201","journal-title":"Psychopharmacology"},{"issue":"10","key":"1133_CR9","doi-asserted-by":"publisher","first-page":"e22039","DOI":"10.1002\/syn.22039","volume":"72","author":"Yong Kee Choi","year":"2018","unstructured":"Choi YK, Tarazi FI (2018) Long-term effects of iloperidone on cerebral dopamine receptor subtypes. Synapse. https:\/\/doi.org\/10.1002\/syn.22039","journal-title":"Synapse"},{"key":"1133_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1017\/S1461145709990824","volume":"13","author":"YK Choi","year":"2010","unstructured":"Choi YK, Wong EH, Henry B, Shahid M, Tarazi FI (2010) Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol 13:405\u2013410","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"1133_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1017\/S1092852916000894","volume":"22","author":"YK Choi","year":"2017","unstructured":"Choi YK, Adham N, Kiss B, Gyerty\u00e1n I, Tarazi FI (2017) Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine. CNS Spectr 22(6):484\u2013494","journal-title":"CNS Spectr"},{"issue":"2","key":"1133_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1527-3458.1997.tb00320.x","volume":"3","author":"R Corbett","year":"1997","unstructured":"Corbett R, Griffiths L, Shipley JE, Shukla U, Strupczewskim JT, Szczepanik AM, Szewczak MR, Turk DJ, Vargas HM, Kongsamut S (1997) Iloperidone: preclinical profile and early clinical evaluation. CNS Drug Rev 3(2):120\u2013147","journal-title":"CNS Drug Rev"},{"key":"1133_CR13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fnhum.2013.00238","volume":"7","author":"C Deng","year":"2013","unstructured":"Deng C, Dean B (2013) Mapping the pathophysiology of schizophrenia: interactions between multiple cellular pathways. Front Cell Neurosci 7:238","journal-title":"Front Cell Neurosci"},{"key":"1133_CR14","doi-asserted-by":"publisher","first-page":"10831","DOI":"10.1523\/JNEUROSCI.2999-05.2005","volume":"25","author":"L D\u00edaz-Mataix","year":"2005","unstructured":"D\u00edaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F (2005) Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25:10831\u201310843","journal-title":"J Neurosci"},{"issue":"2","key":"1133_CR15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-3565(24)36475-4","volume":"280","author":"WJ Florijn","year":"1997","unstructured":"Florijn WJ, Tarazi FI, Creese I (1997) Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 280(2):561\u2013569","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1133_CR16","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0022-3565(25)11149-X","volume":"261","author":"PT Francis","year":"1992","unstructured":"Francis PT, Pangalos MN, Pearson RC, Middlemiss DN, Stratmann GC, Bowen DM (1992) 5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J Pharmacol Exp Ther 261(3):1273\u20131281","journal-title":"J Pharmacol Exp Ther"},{"key":"1133_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.bi.56.070187.003151","volume":"56","author":"AG Gilman","year":"1987","unstructured":"Gilman AG (1987) G proteins: transducers of receptor-generated signals. Annu Rev Biochem 56:615\u2013649","journal-title":"Annu Rev Biochem"},{"key":"1133_CR18","first-page":"462","volume-title":"Econometric analysis","author":"WH Greene","year":"2000","unstructured":"Greene WH (2000) Econometric analysis, 4th edn. Prentice Hall, Upper Saddle River, pp 462\u2013465","edition":"4"},{"key":"1133_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/0006-8993(94)01338-I","volume":"672","author":"AL Gundlach","year":"1995","unstructured":"Gundlach AL, Burazin TC, Jenkins TA, Berkovic SF (1995) Spatiotemporal alterations of central alpha 1-adrenergic receptor binding sites following amygdaloid kindling seizures in the rat: autoradiographic studies using [3H]prazosin. Brain Res 672:214\u2013227","journal-title":"Brain Res"},{"key":"1133_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0006-3223(97)00321-1","volume":"42","author":"EV Gurevich","year":"1997","unstructured":"Gurevich EV, Joyce JN (1997) Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 42:529\u2013545","journal-title":"Biol Psychiatry"},{"key":"1133_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neuroscience.2003.09.004","volume":"123","author":"HK Happe","year":"2004","unstructured":"Happe HK, Coulter CL, Gerety ME, Sanders JD, O\u2019Rourke M, Bylund DB, Murrin LC (2004) Alpha-2 adrenergic receptor development in rat CNS: an autoradiographic study. Neuroscience 123:167\u2013178","journal-title":"Neuroscience"},{"key":"1133_CR22","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1007\/BF02245005","volume":"112","author":"T Hashimoto","year":"1993","unstructured":"Hashimoto T, Kitamura N, Kajimoto Y, Shirai Y, Shirakawa O, Mita T, Nishino N, Tanaka C (1993) Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology 112:S35\u2013S39","journal-title":"Psychopharmacology"},{"issue":"1\u20133","key":"1133_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.schres.2014.09.041","volume":"167","author":"S Heckers","year":"2015","unstructured":"Heckers S, Konradi C (2015) GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophr Res 167(1\u20133):4\u201311","journal-title":"Schizophr Res"},{"key":"1133_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1126\/science.286.5437.105","volume":"286","author":"P Hertel","year":"1999","unstructured":"Hertel P, Fagerquist MV, Svensson TH (1999) Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286:105\u2013107","journal-title":"Science"},{"key":"1133_CR25","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","volume":"76","author":"J Ichikawa","year":"2001","unstructured":"Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O\u2019Laughlin IA, Meltzer HY (2001) 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521\u20131531","journal-title":"J Neurochem"},{"issue":"8","key":"1133_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.tips.2010.05.004","volume":"31","author":"CS Karam","year":"2010","unstructured":"Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE, Mark S, Lieberman JA, Javitch JA (2010) Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci 31(8):381\u2013390","journal-title":"Trends Pharmacol Sci"},{"key":"1133_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0014-2999(96)00840-0","volume":"317","author":"S Kongsamut","year":"1996","unstructured":"Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A (1996) Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 317:417\u2013423","journal-title":"Eur J Pharmacol"},{"key":"1133_CR28","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1001\/archpsyc.1993.01820220066007","volume":"50","author":"M Laruelle","year":"1993","unstructured":"Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE (1993) Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry 50:810\u2013818","journal-title":"Arch Gen Psychiatry"},{"key":"1133_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31\u201341","journal-title":"Lancet"},{"issue":"7","key":"1133_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1017\/S1461145709990794","volume":"13","author":"MM Marcus","year":"2010","unstructured":"Marcus MM, Wiker C, Fr\u00e5nberg O, Konradsson-Geuken A, Langlois X, Jardemark K, Svensson TH (2010) Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int J Neuropsychopharmacol 13(7):891\u2013903","journal-title":"Int J Neuropsychopharmacol"},{"key":"1133_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0014-2999(98)00945-5","volume":"367","author":"GJ Marek","year":"1999","unstructured":"Marek GJ, Aghajanian GK (1999) 5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol 367:197\u2013206","journal-title":"Eur J Pharmacol"},{"key":"1133_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","volume":"64","author":"HY Meltzer","year":"2013","unstructured":"Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64:393\u2013406","journal-title":"Annu Rev Med"},{"key":"1133_CR33","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","volume":"27","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 27:1159\u20131172","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"3","key":"1133_CR34","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-3565(24)38982-7","volume":"295","author":"MJ Millan","year":"2000","unstructured":"Millan MJ (2000) Improving the treatment of schizophrenia: focus on serotonin 5-HT1A receptors. J Pharmacol Exp Ther 295(3):853\u2013861","journal-title":"J Pharmacol Exp Ther"},{"key":"1133_CR35","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1038\/npp.2012.68","volume":"37","author":"DA Mitrano","year":"2012","unstructured":"Mitrano DA, Schroeder JP, Smith Y, Cortright JJ, Bubula N, Vezina P, Weinshenker D (2012) \u03b11 adrenergic receptors are localized on presynaptic elements in the nucleus accumbens and regulate mesolimbic dopamine transmission. Neuropsychopharmacology 37:2161\u20132172","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1133_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/syn.10189","volume":"48","author":"I Ninan","year":"2003","unstructured":"Ninan I, Jardemark KE, Wang RY (2003) Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48(2):66\u201379","journal-title":"Synapse"},{"issue":"4","key":"1133_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/026988119400800401","volume":"8","author":"DJ Nutt","year":"1994","unstructured":"Nutt DJ (1994) Putting the \u2018A\u2019 in atypical: does \u03b12-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J Psychopharmacol 8(4):193\u2013195","journal-title":"J Psychopharmacol"},{"key":"1133_CR38","unstructured":"Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. 2nd edn. Academic, Cambridge"},{"issue":"2","key":"1133_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/0006-8993(85)90856-X","volume":"346","author":"A Pazos","year":"1985","unstructured":"Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346(2):205\u2013230","journal-title":"Brain Res"},{"key":"1133_CR40","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1523\/JNEUROSCI.12-02-00440.1992","volume":"12","author":"M Pompeiano","year":"1992","unstructured":"Pompeiano M, Palacios JM, Mengod G (1992) Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J Neurosci 12:440\u2013453","journal-title":"J Neurosci"},{"key":"1133_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.brainres.2005.08.049","volume":"1061","author":"OL Pudovkina","year":"2005","unstructured":"Pudovkina OL, Westerink BH (2005) Functional role of alpha1-adrenoceptors in the locus coeruleus: a microdialysis study. Brain Res 1061:50\u201356","journal-title":"Brain Res"},{"key":"1133_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00213-003-1683-8","volume":"174","author":"BL Roth","year":"2004","unstructured":"Roth BL, Hanizavareh SM, Blum AE (2004) Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 174:17\u201324","journal-title":"Psychopharmacology"},{"issue":"1\u20132","key":"1133_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/BF02245606","volume":"124","author":"A Schotte","year":"1996","unstructured":"Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124(1\u20132):57\u201373","journal-title":"Psychopharmacology"},{"issue":"1","key":"1133_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/0269881107082944","volume":"23","author":"M Shahid","year":"2009","unstructured":"Shahid M, Walker GB, Zorn SH, Wong EH (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23(1):65\u201373","journal-title":"J Psychopharmacol"},{"key":"1133_CR45","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1017\/S1092852913000850","volume":"18","author":"SM Stahl","year":"2013","unstructured":"Stahl SM (2013) Role of \u03b11 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectr 18:285\u2013288","journal-title":"CNS Spectr"},{"key":"1133_CR46","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1021\/jm00007a009","volume":"38","author":"JT Strupczewski","year":"1995","unstructured":"Strupczewski JT, Bordeau KJ, Chiang Y, Glamkowski EJ, Conway PG, Corbett R, Hartman HB, Szewczak MR, Wilmot CA, Helsley GC (1995) 3-[[(Arylox)alkyl]-piperdinyl]-1,2-benzisoxazoles as D2\/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873). J Med Chem 38:1119\u20131131","journal-title":"J Med Chem"},{"key":"1133_CR47","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.pnpbp.2003.09.009","volume":"27","author":"TH Svensson","year":"2003","unstructured":"Svensson TH (2003) Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuro-Psychopharmacol Biol Psychiatry 27:1145\u20131158","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"3","key":"1133_CR48","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0022-3565(25)10685-X","volume":"274","author":"MR Szewczak","year":"1995","unstructured":"Szewczak MR, Corbett R, Rush DK, Wilmot CA, Conway PG, Strupczewski JT, Cornfeldt M (1995) The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther 274(3):1404\u20131413","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1133_CR49","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.molbrainres.2005.06.013","volume":"139","author":"P Szot","year":"2005","unstructured":"Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA (2005) Alpha1-adrenoreceptor in human hippocampus: binding and receptor subtype mRNA expression. Mol Brain Res 139(2):367\u2013371","journal-title":"Mol Brain Res"},{"issue":"13","key":"1133_CR50","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1517\/14656566.2012.712114","volume":"13","author":"FI Tarazi","year":"2012","unstructured":"Tarazi FI, Stahl SM (2012) Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother 13(13):1911\u20131922","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"1133_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00213-002-1016-3","volume":"161","author":"FI Tarazi","year":"2002","unstructured":"Tarazi FI, Zhang K, Baldessarini RJ (2002) Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology 161(3):263\u2013270","journal-title":"Psychopharmacology"},{"issue":"3","key":"1133_CR52","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/0269881108095704","volume":"24","author":"FI Tarazi","year":"2010","unstructured":"Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M (2010) Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol 24(3):341\u2013348","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1133_CR53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","volume":"16","author":"D Tarsy","year":"2002","unstructured":"Tarsy D, Baldessarini RJ, Tarazi FI (2002) Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16(1):23\u201345","journal-title":"CNS Drugs"},{"key":"1133_CR54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/CE.S114094","volume":"11","author":"FS Tonin","year":"2016","unstructured":"Tonin FS, Wiens A, Fernandez-Llimos F, Pontarolo R (2016) Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy. Core Evid 11:49\u201361","journal-title":"Core Evid"},{"key":"1133_CR55","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1017\/S1461145706006638","volume":"10","author":"ML Wadenberg","year":"2007","unstructured":"Wadenberg ML, Wiker C, Svensson TH (2007) Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence. Int J Neuropsychopharmacol 10:191\u2013202","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2 Suppl 1","key":"1133_CR56","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1097\/JCP.0b013e3181694f5a","volume":"28","author":"PJ Weiden","year":"2008","unstructured":"Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD (2008) Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 28(2 Suppl 1):S12\u2013S19","journal-title":"J Clin Psychopharmacol"},{"key":"1133_CR57","first-page":"165","volume-title":"Statistical principles in experimental drug design","author":"BJ Winer","year":"1991","unstructured":"Winer BJ, Brown DR, Michels KM (1991) Statistical principles in experimental drug design, 3rd edn. McGraw-Hill, New York, pp 165\u2013166","edition":"3"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12031-018-1133-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-018-1133-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-018-1133-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T07:58:16Z","timestamp":1751788696000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12031-018-1133-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,9]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["1133"],"URL":"https:\/\/doi.org\/10.1007\/s12031-018-1133-z","relation":{},"ISSN":["0895-8696","1559-1166"],"issn-type":[{"value":"0895-8696","type":"print"},{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,9]]},"assertion":[{"value":"22 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}